Necrosis News and Research

RSS

New drug shows promise in treating Crohn's disease

According to two new studies the drug certolizumab has proved to be a safe and effective treatment for moderate-to-severe Crohn's disease.

21 Jul 2007

Certolizumab pegol effective for patients with Crohn's disease

Mayo Clinic researchers have found that Certolizumab pegol is an effective treatment for adults with Crohn's disease, according to two new studies.

19 Jul 2007

Researchers identify new combination therapy that promotes cancer cell death

Researchers at the University of Pennsylvania School of Medicine identified a combination therapy as a way to sensitize resistant human cancer cells to a treatment currently being tested in clinical trials They propose that the therapy may help to selectively eliminate cancer cells while leaving healthy cells intact, providing a cancer treatment with fewer side effects.

17 Jul 2007

Scientists take exciting approach for attacking cancers

A new study identifies a combination therapy that may sensitize human cancer cells to a promising treatment currently being used in clinical trials.

10 Jul 2007

Rapid evolution of defense genes in plants may produce hybrid incompatibility

One of the basic tenets of evolution is speciation in which populations of the same species become so genetically and morphologically variable that they can be classified as two different species.

10 Jul 2007

Omega-3 polyunsaturated fatty acids protect against retinopathy

Omega-3 polyunsaturated fatty acids protect against the development and progression of retinopathy, a deterioration of the retina, in mice.

26 Jun 2007

Extended exposure to the psoriasis medication etanercept reduces psoriasis severity without increased adverse events

Extended exposure to the psoriasis medication etanercept does not appear to cause more infections or adverse events than placebo, and improvements in several measures of disease severity were observed for up to 96 weeks of therapy, according to a study in the June issue of Archives of Dermatology.

19 Jun 2007

Impaired anti-inflammatory response plays role in pathology of type 2 diabetes

Type 2 diabetes is classified as a metabolic disorder, but a growing number of researchers are beginning to think of it also as a disease of the innate immune system. Inflammation, a key component of the early immune response, is chronically elevated in people with type 2 diabetes.

17 Jun 2007

New data on the performance of meningitis vaccine in West African children

The Meningitis Vaccine Project (MVP) today released new data on the performance of a meningitis vaccine in West African children, suggesting that the new vaccine,expected to sell initially for 40 US cents a dose,will be much more effective in protecting African children and their communities than any vaccine currently on the market in the region.

14 Jun 2007

Percutaneous ethanol injection helps manage bone metastasis in thyroid cancer patients

Percutaneous ethanol injection (PEI), an injection of ethanol (alcohol) through the skin directly into a bone tumor to kill cancer cells, may be a valuable ancillary treatment for thyroid cancer patients whose cancer has spread to the bone.

5 Jun 2007

New method predicts hip joint decay from chemotherapy

St. Jude investigators say they have found the best way for predicting when patients will need future surgery to repair hip joints that have deteriorated because of pediatric leukemia or lymphoma treatment.

27 May 2007

Biologist hopes mosquito can break viral chain

Most people do their best to avoid mosquitoes. But this summer Rollie Clem will play the wary host to his own homegrown swarm of Aedes aegypti, the yellow fever mosquito. He's made a room ready for them, and even a menu.

22 May 2007

Abbott seeks U.S. and E.U. approvals for Humira as a treatment for juvenile rheumatoid arthritis

Abbott has announced it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA (adalimumab) as a treatment for juvenile rheumatoid arthritis (JRA) in the U.S. and juvenile idiopathic arthritis (JIA) in the European Union (EU).

9 May 2007